Trial reportJournal of cosmetic dermatology2026
Enhancing Quality of Life and Emotional Well-Being in Atopic Dermatitis Patients: Clinical Evidence of a Dermocosmetic Lipid-Replenishing Regimen.
Trial report in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enhancing Quality of Life and Emotional Well-Being in Atopic Dermatitis Patients: Clinical Evidence of a Dermocosmetic Lipid-Replenishing Regimen.Journal of cosmetic dermatology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by impaired skin barrier function, xerosis, and pruritus, significantly affecting quality of life (QoL). Effective dermocosmetic strategies are needed to alleviate symptoms and improve well-being.
aimsThis study assessed the efficacy of a lipid-replenishing dermocosmetic regimen, including a cleansing oil and emollient balm (Topicrem, Laboratoires NIGY, France), in adults with moderate to severe AD. PATIENTS/
methodsA 4-week clinical study was conducted under dermatological supervision on 21 adults with moderate to severe AD. Patients applied the DA PROTECT Replenishing Cleansing Oil and Emollient Balm (Topicrem) once or twice daily. Efficacy was evaluated via TransEpidermal Water Loss (TEWL), corneometry, SCORAD (SCORing Atopic Dermatitis) index, and patient-reported outcomes. The impact on QoL was assessed using the Dermatology Life Quality Index (DLQI).
resultsAfter 4 weeks, TEWL decreased by 27%, and skin hydration increased by 89% indicating a reinforced skin barrier and improved moisturization. The SCORAD index improved by 27%, pruritus decreased by 61%, and sleep quality improved by 62%, reflecting reduced disease severity. The DLQI score improved by 68%, demonstrating a strong correlation between the dermocosmetic regimen and enhanced QoL, particularly in items related to symptoms, sleep, social life, and emotional well-being. Patient satisfaction was high, with 81% rating efficacy as "good to very good" and 90% approving cosmetic acceptability.
conclusionThe investigational lipid-replenishing regimen significantly improved skin barrier function, hydration, pruritus relief, and QoL in patients with moderate to severe AD. These findings highlight the importance of dermocosmetic interventions in AD management, reducing discomfort, and enhancing patient well-being.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.